Molecular Heterogeneity of Inflammation and Growth Factor Pathways in Sporadic and Syndromic Colon Cancers: Implications for Prevention and Therapeutic TrialsPOP: 09/15/2014-09/14/2015

散发性和综合征性结肠癌中炎症和生长因子途径的分子异质性：对预防和治疗试验的影响POP：09/15/2014-09/14/2015

• 批准号: 8944482
• 负责人: CHINTHALAPALLY RAO
• 金额: $ 48.2万
• 依托单位国家: 美国
• 财政年份: 2014
• 资助国家: 美国
• 起止时间: 2014-09-15 至 2015-09-14
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8944482
• 关键词: Address; Aftercare; Candidate Disease Gene; Chemoprevention; Chemopreventive Agent; Clinical Chemoprevention; Clinical Trials; Colon Carcinoma; Colonic Polyps; Contractor; Contracts; Drug effect disorder; Ensure; Erlotinib; Gene Expression; Genes; Goals; Growth Factor; Heterogeneity; Histologic; Individual; Inflammation; Molecular; Mucous Membrane; Mutate; Mutation; Normal tissue morphology; Participant; Pathway interactions; Patients; Phase II Clinical Trials; Placebo Control; Polyps; Prevention; Process; Randomized; Resistance; Sampling; Source; Sulindac; Therapeutic; Tissues; colon carcinogenesis; genetic analysis; genetic pedigree; overexpression

The contract is to perform molecular analyses on pre- and post-treatment duodenal and colonic polyps as well as histologically normal tissue from FAP/AFAP participants in an existing randomized, placebo-controlled, phase II clinical trial of sulindac and erlotinib or other appropriately selected chemopreventive agents. The ultimate goal shall be to correlate the pathways that contain these markers with mechanisms of colon carcinogenesis and of drug action in inhibiting this process.

该合同是对治疗前和治疗后的十二指肠和结肠息肉以及来自FAP/AFAP参与者的组织学正常组织进行分子分析，这些参与者正在进行一项随机、安慰剂对照的II期临床试验，该试验使用舒林他和厄洛替尼或其他适当选择的化学预防药物。最终目标应该是将含有这些标记物的途径与结肠癌发生机制和抑制这一过程的药物作用联系起来。